



Toxicological Profile for 2-Butanone

Draft for Public Comment

May 2019



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
1600 Clifton Road, N.E.
Mail Stop S102-1
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
May 2019	Update of data in Chapters 2, 3, and 7
December 2010	Addendum to the toxicological profile released
July 1992	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

G. Daniel Todd, Ph.D.

Julie Melia, Ph.D., D.A.B.T.

ATSDR, Division of Toxicology and Human Health
Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice.

PEER REVIEWERS

1. G.A. Shakeel Ansari, Ph.D.; Professor, Department of Pathology; University of Texas Medical Branch; Galveston, Texas
2. F. Peter Guengerich, Ph.D.; Tadashi Inagami Professor of Biochemistry; Department of Biochemistry; Vanderbilt University School of Medicine; Nashville, Tennessee
3. Dale Hattis, Ph.D.; Research Professor, George Perkins Marsh Institute; Clark University; Worcester, Massachusetts

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER.....	ii
FOREWORD.....	iii
VERSION HISTORY.....	v
CONTRIBUTORS & REVIEWERS.....	vi
CONTENTS.....	vii
LIST OF FIGURES.....	ix
LIST OF TABLES.....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH.....	1
1.1 OVERVIEW AND U.S. EXPOSURES.....	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs).....	7
CHAPTER 2. HEALTH EFFECTS.....	10
2.1 INTRODUCTION.....	10
2.2 DEATH.....	27
2.3 BODY WEIGHT.....	27
2.4 RESPIRATORY.....	28
2.5 CARDIOVASCULAR.....	30
2.6 GASTROINTESTINAL.....	31
2.7 HEMATOLOGICAL.....	31
2.8 MUSCULOSKELETAL.....	31
2.9 HEPATIC.....	32
2.10 RENAL.....	33
2.11 DERMAL.....	33
2.12 OCULAR.....	34
2.13 ENDOCRINE.....	35
2.14 IMMUNOLOGICAL.....	35
2.15 NEUROLOGICAL.....	36
2.16 REPRODUCTIVE.....	39
2.17 DEVELOPMENTAL.....	40
2.18 OTHER NONCANCER.....	41
2.19 CANCER.....	42
2.20 GENOTOXICITY.....	43
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	46
3.1 TOXICOKINETICS.....	46
3.1.1 Absorption.....	46
3.1.2 Distribution.....	48
3.1.3 Metabolism.....	49
3.1.4 Excretion.....	50
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models.....	51
3.1.6 Animal-to-Human Extrapolations.....	53
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	54
3.3 BIOMARKERS OF EXPOSURE AND EFFECT.....	54
3.3.1 Biomarkers of Exposure.....	55
3.3.2 Biomarkers of Effect.....	57
3.4 INTERACTIONS WITH OTHER CHEMICALS.....	57

CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	63
4.1 CHEMICAL IDENTITY	63
4.2 PHYSICAL AND CHEMICAL PROPERTIES	63
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE	65
5.1 OVERVIEW	65
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	67
5.2.1 PRODUCTION	67
5.2.2 IMPORT/EXPORT	68
5.2.3 USE	68
5.2.4 DISPOSAL	69
5.3 RELEASES TO THE ENVIRONMENT	69
5.3.1 Air	69
5.3.2 Water	70
5.3.3 Soil	71
5.4 ENVIRONMENTAL FATE	71
5.4.1 Transport and Partitioning	71
5.4.2 Transformation and Degradation	72
5.5 LEVELS IN THE ENVIRONMENT	74
5.5.1 Air	75
5.5.2 Water	76
5.5.3 Sediment and Soil	77
5.5.4 Other Media	77
5.6 GENERAL POPULATION EXPOSURE	78
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	79
CHAPTER 6. ADEQUACY OF THE DATABASE	81
6.1 Information on Health Effects	81
6.2 Identification of Data Needs	82
6.3 Ongoing Studies	90
CHAPTER 7. REGULATIONS AND GUIDELINES	91
CHAPTER 8. REFERENCES	93
APPENDICES	
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR 2-BUTANONE	B-1
APPENDIX C. USER'S GUIDE	C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E. GLOSSARY	E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

1-1. Health Effects Found in Humans and Animals Following Inhalation Exposure to 2-Butanone	3
1-2. Health Effects Found in Animals Following Oral Exposure to 2-Butanone	4
1-3. Summary of Sensitive Targets of 2-Butanone – Inhalation.....	8
1-4. Summary of Sensitive Targets of 2-Butanone – Oral.....	9
2-1. Overview of the Number of Studies Examining 2-Butanone Health Effects	12
2-2. Levels of Significant Exposure to 2-Butanone – Inhalation.....	18
2-3. Levels of Significant Exposure to 2-Butanone – Oral.....	24
3-1. Proposed Metabolic Pathways for 2-Butanone.....	49
5-1. Number of NPL Sites with 2-Butanone Contamination	65
6-1. Summary of Existing Health Effects Studies on 2-Butanone By Route and Endpoint	82

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 2-Butanone	9
2-1. Levels of Significant Exposure to 2-Butanone – Inhalation.....	13
2-2. Levels of Significant Exposure to 2-Butanone – Oral.....	22
2-3. Levels of Significant Exposure to 2-Butanone – Dermal.....	26
2-4. Genotoxicity of 2-Butanone <i>In Vivo</i>	43
2-5. Genotoxicity of 2-Butanone <i>In Vitro</i>	43
4-1. Chemical Identity of 2-Butanone.....	63
4-2. Physical and Chemical Properties of 2-Butanone.....	63
5-1. Manufacturers of 2-Butanone in 1989.....	68
5-2. Lowest Limit of Detection Based on Standards	74
5-3. Summary of Environmental Levels of 2-Butanone	74
5-4. 2-Butanone Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	75
5-5. Detection of 2-Butanone in the Groundwater of Hazardous Waste Sites and Landfills.....	77
7-1. Regulations and Guidelines Applicable to 2-Butanone.....	91